If you’re a startup in the pharmaceutical space, you already know that clinical trials are make-or-break for getting your product to market. But before you even dose your first patient, there’s a critical step that can trip you up if you’re not careful: the clinical trial agreement (CTA).

These contracts aren’t just paperwork—they’re the foundation of your trial’s success. A poorly structured CTA can lead to delays, unexpected costs, or even loss of intellectual property. As an attorney who’s negotiated these agreements for years, I’ve seen firsthand how the fine print can make or break a trial. Let’s walk through what you need to know.

What Every Pharma Startup Should Look for in a CTA

A well-drafted CTA is like a roadmap—it lays out who does what, who pays for what, and what happens when things don’t go as planned. Here’s where I see startups get tripped up most often:

First, the purpose and protocol must be crystal clear. If the agreement doesn’t align perfectly with your trial design, you could end up in disputes over responsibilities later. I once worked with a client whose contract vaguely referenced “study-related activities,” which led to a site demanding extra payments for tasks they assumed were included. We had to renegotiate mid-trial—costing time and money.

Second, there’s intellectual property (IP)—a major sticking point. Clinical sites sometimes push for shared ownership of any discoveries made during the trial, even if they’re just using your drug. That’s a hard no. Your IP is your most valuable asset, and you can’t let a site claim rights just because they administered the treatment.

Third, indemnification and insurance. If a patient has an adverse event, who’s on the hook? The sponsor usually bears responsibility—unless the site messed up (like giving the wrong dose). A good CTA makes sure you’re not paying for someone else’s mistakes.

Lastly, termination clauses. Trials can last years, and sometimes sites want an easy exit. But if a site drops out unexpectedly, you could be left scrambling to transfer patients and data. That’s why I always insist on a wind-down period—enough time to transition smoothly without derailing the whole study.

 

When Should You Start Drafting Your CTA?

Earlier than you think.

I’ve had clients come to me after they’ve already selected sites, only to realize the contract negotiations will take months. Academic medical centers, for example, often have lengthy legal reviews. If you wait until the last minute, your trial start date gets pushed back—and delays are expensive.

The best approach? Start drafting your CTA while you’re finalizing your protocol. That way, you can negotiate terms in parallel with site selection.

A few key timing considerations:

Payment schedules—Will you pay sites upfront or based on milestones? Staggered payments can help with cash flow.

Regulatory approvals—Some countries won’t greenlight your trial until the CTA is signed. Build that into your timeline.

Protocol flexibility—Trials evolve. Make sure your agreement allows for minor protocol changes without requiring a full contract amendment.

 

The Bottom Line: Don’t Go It Alone

Clinical trial agreements are dense, packed with legal and regulatory nuances that can sink an unprepared sponsor. I’ve helped startups avoid costly mistakes—like missing indemnification loopholes or giving away too much IP—simply by reviewing the fine print before it’s too late.

If you’re gearing up for a trial, get an attorney who speaks pharma contracts fluently. A few hours of legal review now can save you months of headaches (and millions of dollars) later.

Ready to make sure your CTA is airtight? Let’s talk—click the link below to schedule a call–before the contract becomes a bottleneck!